Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Castle Biosciences, Inc. - Common stock (NQ:CSTL)

18.69 -0.50 (-2.61%)
Streaming Delayed Price Updated: 9:36 AM EDT, Apr 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Castle Biosciences, Inc. - Common stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Recently Published Data Confirm DecisionDx®-SCC as a Significant and Independent Risk-Stratification Tool in Patients with Squamous Cell Carcinoma and One or More Risk Factors
From Castle Biosciences, Inc.
Via Business Wire
Data Published in Ocular Oncology and Pathology Demonstrates Highly Accurate Performance of DecisionDx®-UMSeq for Patients with Uveal Melanoma
From Castle Biosciences, Inc.
Via Business Wire
Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2021 Results
From Castle Biosciences, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For January 7, 2022
Upgrades According to Wolfe Research, the prior rating for CVR Energy Inc (NYSE: 
Via Benzinga
Castle Biosciences to Present at the 24th Annual Needham Growth Conference
From Castle Biosciences, Inc.
Via Business Wire
Castle Biosciences Completes Acquisition of Cernostics
From Castle Biosciences, Inc.
Via Business Wire
Castle Biosciences Presents Data Reinforcing the Clinical Utility of Its DecisionDx® Dermatologic Portfolio
From Castle Biosciences, Inc.
Via Business Wire
Data Demonstrating DecisionDx®-Melanoma Was a Significant, Independent Predictor of Metastatic Recurrence in Stage I-III Cutaneous Melanoma Published in Future Oncology
From Castle Biosciences, Inc.
Via Business Wire
Castle Biosciences Named in Inc.’s First-Annual Best-Led Companies
From Castle Biosciences, Inc.
Via Business Wire
Castle Biosciences Named a 2021 Houston Chronicle Top Workplace
From Castle Biosciences, Inc.
Via Business Wire
Castle Biosciences to Present at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum
From Castle Biosciences, Inc.
Via Business Wire
Castle Biosciences Announces Third Quarter 2021 Results
From Castle Biosciences, Inc.
Via Business Wire
Castle Biosciences Releases Inaugural Environmental, Social and Governance (ESG) Report
From Castle Biosciences, Inc.
Via Business Wire
Castle Biosciences Publishes DecisionDx®-Melanoma Study on the Validation of the i31-GEP SLNB Artificial Intelligence Algorithm
From Castle Biosciences, Inc.
Via Business Wire
Castle Biosciences’ Full DecisionDx® Portfolio of Dermatologic Tests to Be Interfaced with EMA® Electronic Health Records System
From Castle Biosciences, Inc.
Via Business Wire
DecisionDx®-Melanoma Integrated Test Result Now Includes i31-GEP for Risk of Recurrence
From Castle Biosciences, Inc.
Via Business Wire
New Data Demonstrating Accuracy of DecisionDx® DiffDx™-Melanoma Presented at ASDP 58th Annual Meeting
From Castle Biosciences, Inc.
Via Business Wire
Castle Biosciences to Release Third Quarter 2021 Financial Results and Host Conference Call on Monday, Nov. 8, 2021
From Castle Biosciences, Inc.
Via Business Wire
Castle Biosciences Presents Data from Suite of Dermatologic Cancer Genomic Tests at Fall Clinical Dermatology Conference 2021
From Castle Biosciences, Inc.
Via Business Wire
Castle Biosciences to Acquire Cernostics
From Castle Biosciences, Inc.
Via Business Wire
Castle Biosciences President and CEO Derek Maetzold Will Deliver Keynote Presentation During Arizona Bioscience Week
From Castle Biosciences, Inc.
Via Business Wire
Castle Biosciences's Return On Capital Employed Overview
Castle Biosciences (NASDAQ:CSTL) brought in sales totaling $22.76 million during Q2 according to data provided by Benzinga Pro. However, earnings decreased 105.65%, resulting in a... 
Via Benzinga
Castle Biosciences Announces New York Approval of DecisionDx® DiffDx™-Melanoma
From Castle Biosciences
Via Business Wire
Castle Biosciences Recognized as a Top 100 Healthcare Technology Company of 2021
From Castle Biosciences, Inc.
Via Business Wire
Castle Biosciences to Present at Upcoming Investor Conferences
From Castle Biosciences, Inc.
Via Business Wire
Castle Biosciences Awarded U.S. Federal Supply Schedule Contract for DecisionDx-Melanoma
From Castle Biosciences, Inc.
Via Business Wire
The Daily Biotech Pulse: Cara's Korsuva Greenlighted By FDA, Clinical Trial Disappointments For Novartis, Theravance, Vertex Inks CRISPR Licensing Deal
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 23) AbbVie Inc. (NYSE: ABBV) (... 
Via Benzinga
Exposures Product Safety
Castle Biosciences Presents New Data on DecisionDx®-Melanoma and DecisionDx®-SCC at the 2021 American Academy of Dermatology (AAD) Summer Meeting
From Castle Biosciences, Inc.
Via Business Wire
Castle Biosciences Q2 Earnings Edges Out Expectation On Record Test Report Volume
After the market close on Monday, Castle Biosciences Inc (NASDAQ: CSTL) reported that its second-quarter revenues rose 79% Y/Y to $22.75 million, beating the... 
Via Benzinga
Castle Biosciences Announces Second Quarter 2021 Results
From Castle Biosciences, Inc.
Via Business Wire
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.